{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T05:08:03Z","timestamp":1768626483558,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,1,12]],"date-time":"2013-01-12T00:00:00Z","timestamp":1357948800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s10928-012-9296-7","type":"journal-article","created":{"date-parts":[[2013,1,11]],"date-time":"2013-01-11T01:28:43Z","timestamp":1357867723000},"page":"377-388","source":"Crossref","is-referenced-by-count":13,"title":["Modelling and simulation of placebo effect: application to drug development in schizophrenia"],"prefix":"10.1007","volume":"40","author":[{"given":"Venkatesh","family":"Pilla Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Kozielska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rik","family":"de Greef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An","family":"Vermeulen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes H.","family":"Proost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,1,12]]},"reference":[{"issue":"2","key":"9296_CR1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261\u2013276","journal-title":"Schizophr Bull"},{"issue":"2","key":"9296_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrd3375","volume":"10","author":"J Arrowsmith","year":"2011","unstructured":"Arrowsmith J (2011) TRIAL WATCH Phase III and submission failures: 2007\u20132010. Nat Rev Drug Discov 10(2):1","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"9296_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrd3439","volume":"10","author":"J Arrowsmith","year":"2011","unstructured":"Arrowsmith J (2011) Phase II failures: 2008\u20132010. Nat Rev Drug Discov 10(5):1","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"9296_CR4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0924-977X(97)00081-3","volume":"8","author":"JG Storosum","year":"1998","unstructured":"Storosum JG, Elferink AJ, van Zwieten BJ (1998) Schizophrenia: do we really need placebo-controlled studies? Eur Neuropsychopharmacol 8(4):279\u2013286","journal-title":"Eur Neuropsychopharmacol"},{"issue":"3","key":"9296_CR5","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000069738","volume":"72","author":"M Fava","year":"2003","unstructured":"Fava M, Evins AE, Dorer DJ, Schoenfeld DA (2003) The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach. Psychother Psychosom 72(3):115\u2013127","journal-title":"Psychother Psychosom"},{"issue":"2","key":"9296_CR6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/schbul\/sbm159","volume":"34","author":"S Leucht","year":"2008","unstructured":"Leucht S, Heres S, Hamann J, Kane JM (2008) Methodological issues in current antipsychotic drug trials. Schizophr Bull 34(2):275\u2013285","journal-title":"Schizophr Bull"},{"key":"9296_CR7","doi-asserted-by":"crossref","unstructured":"Pilla Reddy V, Kozielska M, Johnson M, Vermeulen A, de Greef R, Liu J, Groothuis GM, Danhof M, Proost JH (2011) Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders. Clin Pharmacokinet 50(7):429\u2013450","DOI":"10.2165\/11590590-000000000-00000"},{"key":"9296_CR8","doi-asserted-by":"crossref","unstructured":"Finniss DG, Kaptchuk TJ, Miller F, Benedetti F (2010) Biological, clinical, and ethical advances of placebo effects. Lancet 375(9715):686\u2013695","DOI":"10.1016\/S0140-6736(09)61706-2"},{"issue":"7004","key":"9296_CR9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1136\/bmj.311.7004.551","volume":"311","author":"E Ernst","year":"1995","unstructured":"Ernst E, Resch KL (1995) Concept of true and perceived placebo effects. BMJ 311(7004):551\u2013553","journal-title":"BMJ"},{"issue":"1","key":"9296_CR10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.clpt.6100234","volume":"82","author":"JR Powell","year":"2007","unstructured":"Powell JR, Gobburu JVS (2007) Pharmacometrics at FDA: evolution and impact on decisions. Clin Pharmacol Ther 82(1):97\u2013102","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"9296_CR11","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/schbul\/sbn110","volume":"36","author":"AS Kemp","year":"2010","unstructured":"Kemp AS, Schooler NR, Kalali AH, Alphs L, Anand R, Awad G, Davidson M, Dube S, Ereshefsky L, Gharabawi G, Leon AC, Lepine JP, Potkin SG, Vermeulen A (2010) What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull 36(3):504\u2013509","journal-title":"Schizophr Bull"},{"issue":"3","key":"9296_CR12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0009-9236(97)90160-0","volume":"61","author":"LB Sheiner","year":"1997","unstructured":"Sheiner LB (1997) Learning versus confirming in clinical drug development. Clin Pharmacol Ther 61(3):275\u2013291","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"9296_CR13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/clpt.2009.44","volume":"86","author":"LE Friberg","year":"2009","unstructured":"Friberg LE, de Greef R, Kerbusch T, Karlsson MO (2009) Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther 86(1):84\u201391","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"9296_CR14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ejps.2008.10.025","volume":"36","author":"R Gomeni","year":"2009","unstructured":"Gomeni R, Lavergne A, Merlo-Pich E (2009) Modelling placebo response in depression trials using a longitudinal model with informative dropout. Eur J Pharm Sci 36(1):4\u201310","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"9296_CR15","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/11598460-000000000-00000","volume":"51","author":"V Pilla Reddy","year":"2012","unstructured":"Pilla Reddy V, Kozielska M, Johnson M, Suleiman AA, Vermeulen A, Liu J, de Greef R, Groothuis GM, Danhof M, Proost JH (2012) Modelling and simulation of the positive and negative syndrome scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials. Clin Pharmacokinet 51(4):261\u2013275","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"9296_CR16","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4088\/JCP.11r07539","volume":"73","author":"NA Khin","year":"2012","unstructured":"Khin NA, Chen YF, Yang Y, Yang P, Laughren TP (2012) Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. J Clin Psychiatry 73(6):856\u2013864","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"9296_CR17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/clpt.2012.88","volume":"92","author":"N Holford","year":"2012","unstructured":"Holford N (2012) Modeling helps in understanding antidepressants. Clin Pharmacol Ther 92(2):155\u2013156","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"9296_CR18","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1017\/S1461145711001738","volume":"15","author":"L Alphs","year":"2012","unstructured":"Alphs L, Benedetti F, Fleischhacker WW, Kane JM (2012) Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it? Int J Neuropsychopharmacol 15(7):1003\u20131014","journal-title":"Int J Neuropsychopharmacol"},{"key":"9296_CR19","doi-asserted-by":"crossref","unstructured":"Pilla Reddy V, Petersson KJ, Suleiman AA, Vermeulen A, Proost JH, Friberg LE (2012) Pharmacokinetic-pharmacodynamic modeling of severity levels of extrapyramidal side effects with Markov elements. CPT Pharmacometrics Syst Pharmacol. 1. http:\/\/www.nature.com\/psp\/journal\/v1\/n9\/abs\/psp20129a.html . Accessed 20 Nov 2012","DOI":"10.1038\/psp.2012.9"},{"issue":"2","key":"9296_CR20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/schbul\/sbm161","volume":"34","author":"J Rabinowitz","year":"2008","unstructured":"Rabinowitz J, Davidov O (2008) The association of dropout and outcome in trials of antipsychotic medication and its implications for dealing with missing data. Schizophr Bull 34(2):286\u2013291","journal-title":"Schizophr Bull"},{"issue":"3","key":"9296_CR21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s002130100711","volume":"155","author":"K Wahlbeck","year":"2001","unstructured":"Wahlbeck K, Tuunainen A, Ahokas A, Leucht S (2001) Dropout rates in randomised antipsychotic drug trials. Psychopharmacology 155(3):230\u2013233","journal-title":"Psychopharmacology"},{"issue":"1","key":"9296_CR22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/A:1023249510224","volume":"30","author":"C Hu","year":"2003","unstructured":"Hu C, Sale ME (2003) A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn 30(1):83\u2013103","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"9296_CR23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1191\/1740774504cn049oa","volume":"1","author":"CH Mallinckrodt","year":"2004","unstructured":"Mallinckrodt CH, Kaiser CJ, Watkin JG, Molenberghs G, Carroll RJ (2004) The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA. Clin Trials 1(6):477\u2013489","journal-title":"Clin Trials"},{"key":"9296_CR24","unstructured":"Petersson KJ, Vermeulen AM, Friberg LE (2009) Could prolactin levels be a more informative predictor for clinical effect of D2-receptor antagonists than drug concentrations in the treatment of schizophrenia? (abstract no. 1541). In: 18th annual meeting, Population Approach Group in Europe; 2009 Jun 23\u201325; St Petersburg [online]. http:\/\/www.page-meeting.org\/default.asp?abstract=1541 . Accessed 25 Sept 2012"},{"key":"9296_CR25","unstructured":"Pilla Reddy V (2012) Translational PKPD modeling in schizophrenia: linking receptor occupancy of antipsychotics to efficacy and safety. Dissertation, University of Groningen, Groningen. http:\/\/dissertations.ub.rug.nl\/faculties\/science\/2012\/v.p.reddy\/ . Accessed 20 Nov 2012"},{"issue":"2","key":"9296_CR26","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/clpt.2011.197","volume":"91","author":"N Goyal","year":"2012","unstructured":"Goyal N, Gomeni R (2012) A novel metric to assess the clinical utility of a drug in the presence of efficacy and dropout information. Clin Pharmacol Ther 91(2):215\u2013219","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"9296_CR27","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jpsychires.2011.03.001","volume":"45","author":"CH Mallinckrodt","year":"2011","unstructured":"Mallinckrodt CH, Tamura RN, Tanaka Y (2011) Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials. J Psychiatr Res 45(9):1202\u20131207","journal-title":"J Psychiatr Res"},{"issue":"1","key":"9296_CR28","first-page":"53","volume":"43","author":"CH Mallinckrodt","year":"2010","unstructured":"Mallinckrodt CH, Zhang L, Prucka WR, Millen BA (2010) Signal detection and placebo response in schizophrenia: parallels with depression. Psychopharmacol Bull 43(1):53\u201372","journal-title":"Psychopharmacol Bull"},{"issue":"5","key":"9296_CR29","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/clpt.2010.159","volume":"88","author":"E Merlo-Pich","year":"2010","unstructured":"Merlo-Pich E, Alexander RC, Fava M, Gomeni R (2010) A new population-enrichment strategy to improve efficiency of placebo-controlled clinical trials of antidepressant drugs. Clin Pharmacol Ther 88(5):634\u2013642","journal-title":"Clin Pharmacol Ther"},{"key":"9296_CR30","unstructured":"Medavante, Internet Communication. http:\/\/www.medavante.com\/news\/12-07-31\/FDA_Approves_NDA_Supported_By_MedAvante_Central_Ratings.aspx . Accessed 31 July 2012"},{"issue":"1","key":"9296_CR31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/sj.mp.4001777","volume":"11","author":"TR Insel","year":"2006","unstructured":"Insel TR, Scolnick EM (2006) Cure therapeutics and strategic prevention: raising the bar for mental health research. Mol Psychiatry 11(1):11\u201317","journal-title":"Mol Psychiatry"},{"issue":"5","key":"9296_CR32","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.coph.2011.08.003","volume":"11","author":"P Muglia","year":"2011","unstructured":"Muglia P (2011) From genes to therapeutic targets for psychiatric disorders - what to expect? Curr Opin Pharmacol 11(5):563\u2013571","journal-title":"Curr Opin Pharmacol"},{"issue":"6","key":"9296_CR33","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/schbul\/sbn114","volume":"34","author":"MJ Arranz","year":"2008","unstructured":"Arranz MJ, Kapur S (2008) Pharmacogenetics in psychiatry: are we ready for widespread clinical use? Schizophr Bull 34(6):1130\u20131144","journal-title":"Schizophr Bull"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-012-9296-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-012-9296-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-012-9296-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T01:33:34Z","timestamp":1562549614000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-012-9296-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,12]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["9296"],"URL":"https:\/\/doi.org\/10.1007\/s10928-012-9296-7","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,12]]}}}